Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.

Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-DaGama EM, Koren J 3rd, Modi S, Chiosis G.

Expert Opin Investig Drugs. 2014 May;23(5):611-28. doi: 10.1517/13543784.2014.902442. Epub 2014 Mar 26. Review.

2.

Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.

Kim T, Keum G, Pae AN.

Expert Opin Ther Pat. 2013 Aug;23(8):919-43. doi: 10.1517/13543776.2013.780597. Epub 2013 May 4. Review.

PMID:
23641970
3.

Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.

Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R.

Cancer Treat Rev. 2013 Jun;39(4):375-87. doi: 10.1016/j.ctrv.2012.10.001. Epub 2012 Nov 28. Review.

PMID:
23199899
4.

HSP90 inhibitors for cancer therapy and overcoming drug resistance.

Jhaveri K, Modi S.

Adv Pharmacol. 2012;65:471-517. doi: 10.1016/B978-0-12-397927-8.00015-4. Review.

PMID:
22959035
5.

Heat shock protein 90: a unique chemotherapeutic target.

Cullinan SB, Whitesell L.

Semin Oncol. 2006 Aug;33(4):457-65. Review.

PMID:
16890800
6.

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.

Jhaveri K, Taldone T, Modi S, Chiosis G.

Biochim Biophys Acta. 2012 Mar;1823(3):742-55. doi: 10.1016/j.bbamcr.2011.10.008. Epub 2011 Oct 29. Review.

7.

Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.

Messaoudi S, Peyrat JF, Brion JD, Alami M.

Expert Opin Ther Pat. 2011 Oct;21(10):1501-42. doi: 10.1517/13543776.2011.594041. Epub 2011 Jun 21. Review.

PMID:
21689065
8.

Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.

Soga S, Akinaga S, Shiotsu Y.

Curr Pharm Des. 2013;19(3):366-76. Review.

PMID:
22920907
9.

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.

Workman P, Burrows F, Neckers L, Rosen N.

Ann N Y Acad Sci. 2007 Oct;1113:202-16. Epub 2007 May 18. Review.

PMID:
17513464
10.
11.

Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.

Garg G, Khandelwal A, Blagg BS.

Adv Cancer Res. 2016;129:51-88. doi: 10.1016/bs.acr.2015.12.001. Epub 2016 Feb 10. Review.

PMID:
26916001
12.

Inhibition of HSP90 molecular chaperones: moving into the clinic.

Garcia-Carbonero R, Carnero A, Paz-Ares L.

Lancet Oncol. 2013 Aug;14(9):e358-69. doi: 10.1016/S1470-2045(13)70169-4. Review.

PMID:
23896275
13.
14.

Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?

Isaacs JS.

Expert Opin Investig Drugs. 2005 Jun;14(6):569-89. Review.

PMID:
16004589
15.

Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.

Kumalo HM, Bhakat S, Soliman ME.

Chem Biol Drug Des. 2015 Nov;86(5):1131-60. doi: 10.1111/cbdd.12582. Epub 2015 Jun 11. Review.

PMID:
25958815
16.

Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.

Zaarur N, Gabai VL, Porco JA Jr, Calderwood S, Sherman MY.

Cancer Res. 2006 Feb 1;66(3):1783-91.

17.

The therapeutic target Hsp90 and cancer hallmarks.

Miyata Y, Nakamoto H, Neckers L.

Curr Pharm Des. 2013;19(3):347-65. Review.

PMID:
22920906
18.

Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Stravopodis DJ, Margaritis LH, Voutsinas GE.

Curr Med Chem. 2007;14(29):3122-38. Review.

PMID:
18220746
19.

Inhibiting HSP90 to treat cancer: a strategy in evolution.

Whitesell L, Santagata S, Lin NU.

Curr Mol Med. 2012 Nov 1;12(9):1108-24. Review.

PMID:
22804235
20.

Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.

Brandt GE, Blagg BS.

Curr Top Med Chem. 2009;9(15):1447-61. Review.

Supplemental Content

Support Center